These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 4614096)

  • 41. [Progress in therapy of Parkinsonian syndrome].
    Völler GW
    Hippokrates; 1975 Feb; 46(1):17-33. PubMed ID: 1091605
    [No Abstract]   [Full Text] [Related]  

  • 42. [Psychiatric complications of L-Dopa treatment of parkinsonism].
    Refsum H
    Tidsskr Nor Laegeforen; 1973 Apr; 93(10):680-5. PubMed ID: 4755082
    [No Abstract]   [Full Text] [Related]  

  • 43. [Medical treatment of Parkinson's disease].
    Castaigne P; Rondot P; Ribadeau-Dumas JL
    Ann Med Interne (Paris); 1972 Apr; 123(4):357-64. PubMed ID: 5077040
    [No Abstract]   [Full Text] [Related]  

  • 44. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 45. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

  • 46. L-dopa in neurological disease: current status.
    Yahr MD
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():494-511. PubMed ID: 4561071
    [No Abstract]   [Full Text] [Related]  

  • 47. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 48. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD
    Neurology; 1970 Dec; 20(12):6-13. PubMed ID: 4924343
    [No Abstract]   [Full Text] [Related]  

  • 49. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 50. The clinical pharmacology of levodopa.
    Morgan JP; Bianchine JR
    Ration Drug Ther; 1971 Jan; 5(1):1-8. PubMed ID: 5162935
    [No Abstract]   [Full Text] [Related]  

  • 51. Experimental evaluation of L-dopa penetration in brain.
    De la Torre JC; Mullan S
    Trans Am Neurol Assoc; 1971; 96():227-9. PubMed ID: 5159088
    [No Abstract]   [Full Text] [Related]  

  • 52. Mental symptoms in Parkinsonian patients treated with L-dopa.
    Jenkins RB; Groh RH
    Lancet; 1970 Jul; 2(7665):177-9. PubMed ID: 4193568
    [No Abstract]   [Full Text] [Related]  

  • 53. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 56. L-dopa for parkinsonism.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 58. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
    Pohlmeier H; Schön I; Matussek N
    Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
    [No Abstract]   [Full Text] [Related]  

  • 59. [L-dopa + peripheral decarboxylase antagonist].
    Wiesel FA
    Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
    [No Abstract]   [Full Text] [Related]  

  • 60. [Modern treatment of parkinsonism].
    Birkmayer W; Neumayer E
    Z Neurol; 1972; 202(4):257-80. PubMed ID: 4117647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.